Roche has reported a 7% increase in full-year 2024 sales at constant exchange rates (CER), reaching CHF 60.5bn ($66.9bn). The ...

"The last four or five games here, we’re in those games. So it’s not like there have been just horrible blowouts." ...

The Swiss pharmaceutical company said the FDA backed a label expansion for the Pathway HER2 (4B5) test to identify patients with HR-positive, HER2-ultralow metastatic breast cancer who could be ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast ...

The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out ...

Two Massachusetts men were indicted for COVID-19 fraud, facing charges of wire fraud conspiracy and wire fraud after allegedly filing fake unemployment claims.

So get your questions in now for Art and he will be with you between 4pm and 5pm GMT (11am to 12pm ET) to answer as many as he can ...

Earnings Per Share (EPS) of $1.20, surpassing the estimated $1.17, reflecting the company’s ability to exceed market expectations. Revenue reached approximately $34.1 billion, exceeding forecasts and ...

We recently compiled a list of the Morgan Stanley’s 15 Best European AI Stocks. In this article, we are going to take a look ...

We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare ...